Purified anti-mouse CD4 Antibody

Product Details

Verified Reactivity

Mouse

Antibody Type

Monoclonal

Host Species

Rat

Immunogen

Mouse CTL clone V4

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Preparation

The antibody was purified by affinity chromatography.

Concentration

0.5 mg/ml

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C.

Application

FC - Quality tested
IHC-F, IP - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Additional reported applications (for the relevant formats) include: blocking of CD4⁺ T cell activation^1,4,11, thymocyte costimulation³, in vitro and in vivo depletion^2,5-8, blocking of egg-sperm cell adhesion^1,4, immunohistochemical staining of acetone-fixed frozen sections^9,10, immunoprecipitation^1,2, and spatial biology (IBEX)^12,13. The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation. Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)

1. Dialynas DP, et al. 1983. J. Immunol. 131:2445. (Block, IP)
2. Dialynas DP, et al. 1983. Immunol. Rev. 74:29. (IP, Deplete)
3. Wu L, et al. 1991. J. Exp. Med. 174:1617. (Costim)
4. Godfrey DI, et al. 1994. J. Immunol. 152:4783. (Block)
5. Gavett SH, et al. 1994. Am. J. Respir. Cell. Mol. Biol. 10:587. (Deplete)
6. Schuyler M, et al. 1994. Am. J. Respir. Crit. Care Med. 149:1286. (Deplete)
7. Ghobrial RR, et al. 1989. Clin. Immunol. Immunopathol. 52:486. (Deplete)
8. Israelski DM, et al. 1989. J. Immunol. 142:954. (Deplete)
9. Zheng B, et al. 1996. J. Exp. Med. 184:1083. (IHC)
10. Frei K, et al. 1997. J. Exp. Med. 185:2177. (IHC)
11. Felix NJ, et al. 2007. Nat. Immunol. 8:388. (Block)
12. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
13. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed

Product Citations

1. Zhang S, et al. 2017. Nature.. 10.1038/nature24283. PubMed
2. Chami B, et al. 2017. Sci Rep. 7:10181. PubMed
3. Tsukumo S, et al. 2006. J Immunol. 177:8365. PubMed
4. Kobayashi A, et al. 2021. Front Immunol. 12:650856. PubMed
5. Liao X, et al. 2022. Front Immunol. 12:768813. PubMed
6. Paterson MJ, et al. 2020. PLoS Pathog. 16:e1008733. PubMed
7. Smith CJ, et al. 2018. J Immunol. 200:1580. PubMed
8. Mazor R, et al. 2018. Proc Natl Acad Sci U S A. 115:E733. PubMed
9. Krovi SH, et al. 2019. Proc Natl Acad Sci U S A. 116:22252. PubMed
10. Thelin MA, et al. 2017. Diabetes. 66:2220. PubMed
11. Thi VAD, et al. 2019. Mol Cells. 42:869. PubMed
12. Burrello C, et al. 2018. Front Med (Lausanne). 5:21. PubMed
13. Shirakawa K, et al. 2017. PLoS One. 12:e0186303. PubMed
14. Landuyt AE, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
15. Fernandes V, et al. 2020. PLoS Pathog. 16:e1008464. PubMed
16. Bajaña S, et al. 2021. Front Immunol. 11:577718. PubMed
17. Murata A, et al. 2020. Front Immunol. 11:775. PubMed
18. Wan Mohd Zawawi WFA, et al. 2021. Sci Rep. 11:10278. PubMed
19. Hummel JF, et al. 2020. Mucosal Immunol. 0.720138889. PubMed
20. Rieck M, et al. 2017. Eur J Immunol. 47:677. PubMed
21. Duvvuri M, et al. 2019. Biomater Sci. 7:1863. PubMed
22. Yang J, et al. 2020. Front Immunol. 10:3048. PubMed
23. Prado C, et al. 2021. J Neuroinflammation. 18:292. PubMed
24. Carpenter SM, et al. 2017. PLoS Pathog. 13:e1006704. PubMed
25. Gao J, et al. 2017. Oncol Lett. 14:2954. PubMed
26. Hashimoto K, et al. 2021. J Dermatol Sci. 102:177. PubMed
27. Haque M, et al. 2021. Viruses. 13:. PubMed
28. Mayer JU, et al. 2020. Front Immunol. 11:592325. PubMed
29. Tian K, et al. 2021. J Immunol Res. 2021:6297332. PubMed
30. Hirano J, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
31. Draganov D, et al. 2021. NPJ Breast Cancer. 7:22. PubMed
32. Rossi DC, et al. 2021. J Clin Invest. 131:. PubMed
33. Wabitsch S, et al. 2021. STAR Protoc. 2:100517. PubMed
34. Xie MM, et al. 2017. Eur J Immunol. 47:1136. PubMed
35. Zhou AC, et al. 2017. Front Immunol. 1.136111111. PubMed
36. Niss Arfelt K, et al. 2017. Blood. 129:866. PubMed
37. Stefanescu C, et al. 2021. Front Oncol. 11:765151. PubMed
38. Mostafavi H, et al. 2022. PLoS Pathog. 18:e1010185. PubMed
39. Schafflick D, et al. 2020. Nat Commun. 247:11. PubMed
40. Tan L, et al. 2017. Int J Nanomedicine. 12:3095. PubMed
41. McLeod RL, et al. 2018. Oncotarget. 9:34459. PubMed
42. Jackson JW, et al. 2021. Mol Ther Oncolytics. 22:444. PubMed
43. Mayer KA, et al. 2021. FASEB J. 35:e21217. PubMed
44. Lasrado N, et al. 2021. Microorganisms. 9:. PubMed
45. Shimokawa C et al. 2017. Immunity. 46(5):863-874 . PubMed
46. Sun H, et al. 2018. J Cell Biol. 217:1453. PubMed
47. Chen S, et al. 2018. Immunohorizons. 0.345138889. PubMed
48. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
49. Wang N, et al. 2021. Mol Ther Oncolytics. 20:71. PubMed
50. Skeate JG, et al. 2018. PLoS One. 13:e0191311. PubMed
51. Seelige R, et al. 2018. Sci Rep. 8:13670. PubMed
52. Yang SH, et al. 2017. Front Immunol. 8:1192. PubMed
53. Zhao L, et al. 2018. Nat Med. 24:1536. PubMed
54. Stacey MA, et al. 2017. J Clin Invest. 127:1463. PubMed
55. Sharma M, et al. 2020. Nat Commun. 11:661. PubMed
56. Ma W, et al. 2017. Sci Rep. . 10.1038/s41598-017-15661-6. PubMed
57. Overacre-Delgoffe AE, et al. 2017. Cell. 169:1130. PubMed
58. Elsayed H, et al. 2018. J Virol. 92:e00428. PubMed
59. Gartlan KH, et al. 2019. Blood Adv. 2.110416667. PubMed
60. Hu M, et al. 2008. J Immunol. 180:6593. PubMed
61. Xie D, et al. 2020. Eur J Immunol. 50:1729. PubMed
62. Shokirova H, et al. 2021. Sci Rep. 11:8647. PubMed
63. Leal AS, et al. 2019. Sci Rep. 5.286111111. PubMed
64. Hoves S, et al. 2018. J Exp Med. 215:859. PubMed
65. Hsiao CC, et al. 2021. Cells. 10:. PubMed
66. Horiuchi S, et al. 2021. Sci Immunol. :eabm3131. PubMed
67. Zareie P, et al. 2017. J Neuroinflammation. 0.630555556. PubMed
68. Pierini A, et al. 2017. JCI Insight. 2. PubMed
69. Sprouse ML, et al. 2018. JCI Insight. 3:e97322. PubMed
70. Lee JY, et al. 2018. Front Immunol. 0.678472222. PubMed
71. Liu M, et al. 2018. Diabetologia. 61:2333. PubMed
72. Sharabi A, et al. 2019. JCI Insight. 4:e126294. PubMed
73. Majer O, et al. 2019. Nature. 575:366. PubMed
74. Tao H, et al. 2021. Front Immunol. 12:623280. PubMed
75. Kinosada H, et al. 2017. PLoS Pathog. 10.1371/journal.ppat.1006120. PubMed
76. Matsuo K, et al. 2018. J Invest Dermatol. 138:1764. PubMed
77. Sendler M, et al. 2020. Gastroenterology. 158:253. PubMed
78. Yates K, et al. 2018. Proc Natl Acad Sci U S A. 115:2162. PubMed
79. Zhang H, et al. 2017. J Immunol. 198:2133. PubMed
80. Simula L et al. 2018. Cell reports. 25(11):3059-3073 . PubMed
81. Biton M et al. 2018. Cell. 175(5):1307-1320 . PubMed
82. Zander R, et al. 2017. Cell Rep.. 10.1016/j.celrep.2017.10.077. PubMed
83. De Ponte Conti B, et al. 2021. Elife. 10:. PubMed
84. Chen HW, et al. 2021. Biomedicines. 9:. PubMed
85. Zelazowska MA, et al. 2020. Life Sci Alliance. :3. PubMed
86. Ikezoe T, et al. 2021. Biomolecules. 11:. PubMed
87. Shiozawa S, et al. 2022. iScience. 25:103537. PubMed
88. Chen X, et al. 2019. Methods Mol Biol. 2048:131. PubMed
89. Rosenbaum M, et al. 2019. Nat Commun. 2.05. PubMed
90. Meyers JL, et al. 2018. PLoS One. 13:e0207007. PubMed
91. Floudas A, et al. 2017. J Immunol. 199:707. PubMed
92. Zhang YN, et al. 2021. Sci Adv. 7:eabj3107. PubMed
93. Goh W, et al. 2020. Cell Rep. 33:108285. PubMed
94. Pradhan P, et al. 2017. JCI Insight. 2. PubMed
95. Song K, et al. 2017. Oncotarget. 8:38554. PubMed
96. Akiel M, et al. 2017. Cancer Res. 77:4014. PubMed
97. Duncan CG, et al. 2018. G3 (Bethesda). 0.892361111. PubMed
98. Wilhelmson AS, et al. 2018. Arterioscler Thromb Vasc Biol. 38:1519. PubMed
99. Roussey JA, et al. 2017. J Immunol. 199:3535. PubMed
100. Stefanski HE, et al. 2018. PLoS One. 13:e0198871. PubMed
101. Scortegagna M, et al. 2020. Nat Commun. 11:99. PubMed
102. Brownlie D, et al. 2021. J Immunother Cancer. 9:. PubMed
103. Tsai MS, et al. 2021. Int J Mol Sci. 22:. PubMed
104. Rosenberg J, et al. 2020. Cell Systems. 10(5):433-444. PubMed
105. Scutts SR, et al. 2018. Cell Rep. 25:1953. PubMed
106. Liu J, et al. 2022. Stem Cell Res Ther. 13:247. PubMed
107. Lin Z, et al. 2021. Stem Cells. 39:240. PubMed
108. Zhang Z, et al. 2020. Front Immunol. 1.844444444. PubMed
109. Luu M, et al. 2019. Nat Commun. 10:760. PubMed
110. Di Dalmazi G, et al. 2019. J Immunol. 202:1350. PubMed
111. Dey P, et al. 2020. Cancer Discov. 10:608. PubMed
112. Mohrin M, et al. 2021. Aging Cell. 20:e13313. PubMed
113. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
114. Englezou PC, et al. 2018. Mol Ther Nucleic Acids. 12:118. PubMed
115. Cole C, et al. 2018. Nucleic Acids Res. 46:e62. PubMed
116. Tang-Huau TL, et al. 2021. Viruses. 13: . PubMed
117. Fujimura N, et al. 2016. J Vasc Surg. 64: 46-54. PubMed
118. Zhang J, et al. 2019. Onco Targets Ther. 12:4985. PubMed
119. Zhang N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
120. Whittle JR, et al. 2020. Clin Cancer Res. 26:4120. PubMed
121. Liu H, et al. 2022. Animal Model Exp Med. 5:72. PubMed
122. Krämer TJ, et al. 2019. J Neuroinflammation. 16:163. PubMed
123. Shao Y, et al. 2017. Onco Targets Ther. 10:2675. PubMed
124. He X, et al. 2017. Cancer Biol Ther. 0.815277778. PubMed
125. Kästele V, et al. 2021. Mucosal Immunol. 14:717. PubMed
126. Prabakaran T, et al. 2021. EBioMedicine. 66:103314. PubMed
127. Sutiwisesak R, et al. 2020. PLoS Pathog. 16:e1009000. PubMed

RRID

AB_312686 (BioLegend Cat. No. 100401)
AB_312687 (BioLegend Cat. No. 100402)

Antigen Details

Structure

Ig superfamily, 55 kD

Distribution

Majority of thymocytes, T cell subset

Function

TCR co-receptor, T cell activation

Ligand/Receptor

MHC class II molecule

Cell Type

Dendritic cells, T cells, Thymocytes, Tregs

Biology Area

Immunology

Molecular Family

CD Molecules

Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID

12504 View all products for this Gene ID

UniProt

View information about CD4 on UniProt.org

Documentation

• Technical data sheet
• Certificate of Analysis
• Safety Data Sheet

Reviews

Related Protocols

• Cell Surface Flow Cytometry Staining Protocol

Related Pages & Pathways

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.

TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.

Other Formats

Certificate of Analysis